|1.||Ernstoff, Marc S: 3 articles (02/2015 - 06/2007)|
|2.||Atkins, Michael B: 2 articles (02/2015 - 06/2007)|
|3.||Clark, Joseph I: 2 articles (02/2015 - 06/2007)|
|4.||McDermott, David F: 2 articles (02/2015 - 08/2009)|
|5.||Dutcher, Janice P: 2 articles (02/2015 - 06/2007)|
|6.||Cusi, Maria Grazia: 2 articles (06/2012 - 07/2008)|
|7.||Correale, Pierpaolo: 2 articles (06/2012 - 07/2008)|
|8.||Tagliaferri, Pierosandro: 2 articles (06/2012 - 07/2008)|
|9.||Tassone, Pierfrancesco: 2 articles (06/2012 - 07/2008)|
|10.||Cassell, Delanie J: 2 articles (02/2008 - 03/2006)|
|1.||Renal Cell Carcinoma (Grawitz Tumor)
04/01/1997 - "A large number of clinical trials (typically noncomparative) have established the efficacy of aldesleukin monotherapy in patients with renal cell carcinoma. "
02/01/2015 - "The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma."
12/01/2004 - "This drug profile provides a review of the literature on studies using aldesleukin in patients with metastatic renal cell carcinoma. "
04/01/1997 - "In view of the poor prognosis associated with renal cell carcinoma, efficacy data from clinical trials evaluating aldesleukin, together with the potential for reducing adverse events by changing its route of administration, suggest the drug may be a worthwhile therapy for patients with this disease."
12/01/2004 - "Aldesleukin in advanced renal cell carcinoma."
06/01/2007 - "This phase I study was designed to determine the maximum tolerated dose (MTD) and safety of BAY 50-4798, screen for tumor response, and assess pharmacokinetics. "
06/01/2007 - "BAY 50-4798 was delivered i.v. every 8 h, days 1 to 5 and 15 to 19, and could be repeated after 9 weeks if tumor was stable or responding. "
11/01/2000 - "BAY 50-4798 was also shown to inhibit metastasis in a mouse tumor model. "
11/01/2000 - "Human interleukin 2 (IL-2; Proleukin) is an approved therapeutic for advanced-stage metastatic cancer; however, its use is restricted because of severe systemic toxicity. "
05/15/2015 - "As anti-cancer therapy with IL-2 has revealed substantial toxicities a mutated human IL-2 molecule, termed AIC284 (formerly BAY 50-4798), has been developed to reduce these side effects. "
|3.||HIV Infections (HIV Infection)
02/01/2008 - "We sought to determine the safety, maximum tolerated dose, optimal dose, and preliminary dose efficacy of intermittent subcutaneously (s.c.) administered BAY 50-4798 among patients with HIV infection receiving highly active antiretroviral therapy (HAART) compared with patients receiving HAART alone. "
|4.||Melanoma (Melanoma, Malignant)
05/01/1997 - "However, the risk/benefit profile of aldesleukin in the treatment of melanoma requires further study, particularly after subcutaneous administration. "
12/01/2011 - "Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma."
05/01/1997 - "Thus, aldesleukin has shown modest efficacy in the treatment of metastatic melanoma. "
05/01/2014 - "The data for patients with metastatic melanoma who received ACT with TIL plus aldesleukin following myeloablative chemotherapy and 12-Gy TBI was examined, in order to look at patient characteristics and the natural history of TMA. "
06/01/2007 - "Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer."
|5.||Colonic Neoplasms (Colon Cancer)
07/01/2008 - "Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial)."
06/01/1992 - "Fifteen patients were analyzed: nine patients (four melanoma, one breast, one sarcoma, one colon, and one undifferentiated cancer) received three injections of 10 to 15 x 10(6) tumor cells, spaced 2 weeks apart, and six patients (two melanoma, two renal, one breast, and one colon cancer) received tumor cells admixed with 3 x 10(6) U recombinant interleukin-2 (IL-2) (Proleukin, Cetus, Emeryville, CA, USA) plus a 10-day intravenous infusion of 15 x 10(6) U/kg/day IL-2 after each immunization. "
06/01/2012 - "At this purpose, we have performed an immunologic investigation in advanced colon cancer patients enrolled in an ongoing phase II trial aimed to test the toxicity and the biological and antitumor activity of a novel biochemotherapy regimen combining polychemotherapy with gemcitabine, irinotecan, levofolinic acid, and fluorouracil with cetuximab and with subcutaneous low-dose metronomic aldesleukin (GILFICet regimen). "
|2.||Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
|1.||Highly Active Antiretroviral Therapy (HAART)
|3.||Combination Drug Therapy (Combination Chemotherapy)